Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

NCT02989168 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to lack of clinically meaningful benefit

Conditions

Idiopathic Pulmonary Fibrosis
Hypoxemia

Interventions

DRUG: GBT440

Sponsor

Global Blood Therapeutics